Omnes Capital's investments
Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: [i] a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and [ii] a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. This second program has recently received up to $8.9 million funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Thanks to a simple and fun service, "Geevers" can easily give and receive items for free in the proximity of their own homes. Available in Paris, Lyon, Marseille, Lille, Bordeaux, Nantes and Toulouse, GEEV has become an obvious alternative to selling, unnecessary storage and the proliferation of waste in the public space.
Tilkee was founded by Sylvain Tillon and Timothée Saumet in decembre 2013. The company offers a complete suite of document tracking solutions: Tilkee for Sales, Tilkee for Marketing, Tilkee for Jobs and Tilkee for Events. Tilkee currently employs 24 people and is growing in Europe (Germany, United Kingdom, Spain). Tilkee’s clients include EDF, Orange, Schneider Electric, Credit Agricole and Adecco
ForCity was founded in 2014 and employs over 82 people based in Lille, Lyon, Rennes and Paris.
ForCity provides public authorities and businesses with a simulation tool to help them anticipate such challenges and optimise planning. Their tools enable their users to simulate any and all the scenarios they may want to explore. ForCity is helping to transform the management of services and infrastructures in cities.
ForCity: accredited French Tech prizewinner before its first fundraising initiative.
Founded in 2015, VSORA will introduce innovative DSP IP solutions to accelerate the design of complex integrated circuits, prevalent in the mobile, networking and consumer product markets. It has offices in Velizy-Villacoublay.
Based in Paris, Enterome is an innovative theranostics company dedicated to discovering and developing biomarkers to diagnose and treat inflammatory conditions (Crohn’s disease, ulcerative colitis) linked to anomalies in intestinal composition using a unique platform that harnesses the power of the human microbiome. In addition to its inflammatory franchise, the Enterome platform can also be used for a vast range of applications such as monitoring and treating metabolic conditions (fatty liver, obesity, diabetes).
Themis Bioscience GmbH develops vaccines at the pre-clinical and early clinical stages.
The Vienna-headquartered company specialises in emerging tropical diseases. The first vaccine candidates currently under development target Chikungunya and Dengue fever. Themaxyn®, the innovative platform originally developed at the Pasteur Institute in Paris and protected by a number of patents, represents the vector for all the company’s current vaccine candidates.